Emerging evidence indicates that treatment context profoundly affects
psychopharmacological interventions. We review the evidence for the interaction between …

While pharmacological treatments for psychiatric disorders have offered great promise and
have provided clinically meaningful symptom relief these treatments have had less effect on …

Antipsychotic drugs, all of which block the dopamine D2 receptor to a greater or lesser
extent, are the mainstay for the pharmacological treatment of schizophrenia. Engaging in a …

The discipline of psychiatry appears poised at the edge of a paradigm shift. Enthusiasm
about psychopharmacological treatments and neuroscientific understandings is giving way …

As psychedelic compounds gain traction in psychiatry, there is a need to consider the active
mechanism to explain the effect observed in randomized clinical trials. Traditionally …

Until recently, the actions of antipsychotic and pro-psychotic drugs have largely been
evaluated in the framework of neuronal doctrine–namely, that neurons communicate by …

We are currently facing the challenge of improving treatments for psychiatric disorders such
as major depression. Notably, antidepressants have an incomplete efficacy, mostly due to …

Environmental contexts that are reliably associated with the use of pharmacologically active
substances are hypothesized to contribute to substance use disorders. In this review, we …

How does a small molecule blocking a few receptors change a patients' passionately held
paranoid belief that the FBI is out to get him? To address this central puzzle of antipsychotic …

What is known and Objective: Psychotherapy has traditionally competed with
psychopharmacology. As drugs have become the more dominant treatment in psychiatry …